Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly Population
Background: quadrivalent inactivated vaccine (QIV) has replaced trivalent inactivated vaccine (TIV). In Portugal, TIV is free of charge for risk groups, including older adults (≥65 years old). In its turn, QIV—which provides broader protection as it includes an additional lineage B strain—was introd...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/8/1285 |
| _version_ | 1827617489030217728 |
|---|---|
| author | Diana Tavares Helena Mouriño Cristina Antón Rodríguez Carlos Martín Saborido |
| author_facet | Diana Tavares Helena Mouriño Cristina Antón Rodríguez Carlos Martín Saborido |
| author_sort | Diana Tavares |
| collection | DOAJ |
| description | Background: quadrivalent inactivated vaccine (QIV) has replaced trivalent inactivated vaccine (TIV). In Portugal, TIV is free of charge for risk groups, including older adults (≥65 years old). In its turn, QIV—which provides broader protection as it includes an additional lineage B strain—was introduced in Portugal in October 2018; only since the 2019/20 influenza season has it been provided free of charge for risk groups. This study evaluates the cost effectiveness of switching from TIV to QIV, from the National Health Service perspective, in the Portuguese elderly mainland population. Methods: A decision tree model was developed to compare TIV and QIV, based on Portuguese hospitalization data for the 2015/16 influenza season. The primary health economic outcome under consideration was the incremental cost-effectiveness ratio (ICER). In addition, one-way sensitivity analysis and probabilistic sensitivity analysis were performed. Results: the high cost of QIV (approximately three times the cost of TIV) would lead to a total increment of EUR 5,283,047, and the resulting ICER would be EUR 26,403,007/QALY, above the usual willingness-to-pay threshold. Conclusions: from the National Health Service perspective, our findings reveal that QIV is not cost effective for the Portuguese elderly population due to the high cost. If the QIV costs were the same as the TIV, then QIV would be cost effective. |
| first_indexed | 2024-03-09T09:47:44Z |
| format | Article |
| id | doaj.art-53079fe056da421ca288005cdc2eb8b6 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T09:47:44Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-53079fe056da421ca288005cdc2eb8b62023-12-02T00:25:28ZengMDPI AGVaccines2076-393X2022-08-01108128510.3390/vaccines10081285Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly PopulationDiana Tavares0Helena Mouriño1Cristina Antón Rodríguez2Carlos Martín Saborido3Faculdade de Ciências, Universidade de Lisboa, 1749-016 Lisboa, PortugalFaculdade de Ciências, Universidade de Lisboa, 1749-016 Lisboa, PortugalFacultad de Medicina, Universidad Francisco de Vitoria Madrid, 28223 Madrid, SpainMinistry of Health, 28014 Madrid, SpainBackground: quadrivalent inactivated vaccine (QIV) has replaced trivalent inactivated vaccine (TIV). In Portugal, TIV is free of charge for risk groups, including older adults (≥65 years old). In its turn, QIV—which provides broader protection as it includes an additional lineage B strain—was introduced in Portugal in October 2018; only since the 2019/20 influenza season has it been provided free of charge for risk groups. This study evaluates the cost effectiveness of switching from TIV to QIV, from the National Health Service perspective, in the Portuguese elderly mainland population. Methods: A decision tree model was developed to compare TIV and QIV, based on Portuguese hospitalization data for the 2015/16 influenza season. The primary health economic outcome under consideration was the incremental cost-effectiveness ratio (ICER). In addition, one-way sensitivity analysis and probabilistic sensitivity analysis were performed. Results: the high cost of QIV (approximately three times the cost of TIV) would lead to a total increment of EUR 5,283,047, and the resulting ICER would be EUR 26,403,007/QALY, above the usual willingness-to-pay threshold. Conclusions: from the National Health Service perspective, our findings reveal that QIV is not cost effective for the Portuguese elderly population due to the high cost. If the QIV costs were the same as the TIV, then QIV would be cost effective.https://www.mdpi.com/2076-393X/10/8/1285influenza vaccinesdecision treecost effectiveness analysisone-way sensitivity analysisprobabilistic sensitivity analysis |
| spellingShingle | Diana Tavares Helena Mouriño Cristina Antón Rodríguez Carlos Martín Saborido Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly Population Vaccines influenza vaccines decision tree cost effectiveness analysis one-way sensitivity analysis probabilistic sensitivity analysis |
| title | Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly Population |
| title_full | Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly Population |
| title_fullStr | Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly Population |
| title_full_unstemmed | Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly Population |
| title_short | Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly Population |
| title_sort | cost effectiveness of quadrivalent versus trivalent inactivated influenza vaccines for the portuguese elderly population |
| topic | influenza vaccines decision tree cost effectiveness analysis one-way sensitivity analysis probabilistic sensitivity analysis |
| url | https://www.mdpi.com/2076-393X/10/8/1285 |
| work_keys_str_mv | AT dianatavares costeffectivenessofquadrivalentversustrivalentinactivatedinfluenzavaccinesfortheportugueseelderlypopulation AT helenamourino costeffectivenessofquadrivalentversustrivalentinactivatedinfluenzavaccinesfortheportugueseelderlypopulation AT cristinaantonrodriguez costeffectivenessofquadrivalentversustrivalentinactivatedinfluenzavaccinesfortheportugueseelderlypopulation AT carlosmartinsaborido costeffectivenessofquadrivalentversustrivalentinactivatedinfluenzavaccinesfortheportugueseelderlypopulation |